Combined modality treatment with ABI-007, nanoparticle albumin-bound (nab) paclitaxel:: modification of radiation response in vivo

被引:0
|
作者
Wiedenmann, N. [1 ,2 ]
Valdecanas, D. [2 ]
Hunter, N. [2 ]
Farrar, D. [2 ]
Milas, L. [2 ]
Mason, K. [2 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Strahlentherapie & Radiol Onkol, D-8000 Munich, Germany
[2] Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A13
引用
收藏
页码:97 / 97
页数:1
相关论文
共 50 条
  • [41] A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P)
    Abu-Khalaf, M. M.
    Gettinger, S. N.
    Trieu, V. N.
    Deshpande, H. A.
    DiGiovanna, M.
    Azodi, M.
    Desai, N.
    Kelly, W. K.
    Schwartz, P. E.
    Harris, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
    Cortes, Javier
    Saura, Cristina
    EJC SUPPLEMENTS, 2010, 8 (01): : 1 - 10
  • [43] Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
    Huang, Yan
    Liang, Wenhua
    Yang, Yunpeng
    Zhao, Liping
    Zhao, Hongyun
    Wu, Xuan
    Zhao, Yuanyuan
    Zhang, Yang
    Zhang, Li
    BMC CANCER, 2016, 16
  • [44] Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
    Yan Huang
    Wenhua Liang
    Yunpeng Yang
    Liping Zhao
    Hongyun Zhao
    Xuan Wu
    Yuanyuan Zhao
    Yang Zhang
    Li Zhang
    BMC Cancer, 16
  • [45] Interim results of PEANUT: pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC)
    Necchi, Andrea
    Raggi, Daniele
    Bandini, Marco
    Fare, Elena
    Giannatempo, Patrizia
    Colecchia, Maurizio
    Pederzoli, Filippo
    Gallina, Andrea
    Marandino, Laura
    Calareso, Giuseppina
    Madison, Russell
    Briganti, Alberto
    Ross, Jeffrey S.
    Montorsi, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [46] Final results of PEANUT: Pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC).
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Bandini, Marco
    Marandino, Laura
    Raggi, Daniele
    Fare, Elena
    Colecchia, Maurizio
    Pederzoli, Filippo
    Gallina, Andrea
    Madison, Russell
    Briganti, Alberto
    Ross, Jeffrey S.
    Montorsi, Francesco
    Necchi, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Weekly nanoparticle albumin paclitaxel (ABI-007) results in long-term disease control in patients with taxane-refractory metastatic breast cancer
    Blum, J. L.
    O'Shaughnessy, J. A.
    Sandbach, J.
    Savin, M.
    Fenske, E.
    Hawkins, Michael J.
    ANNALS OF ONCOLOGY, 2004, 15 : 30 - 30
  • [48] Cost-effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs Cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC).
    Gradishar, W
    Wolinsky, S
    Vishalpura, T
    Nightengale, B
    Bramley, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 36S - 36S
  • [49] Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma
    Shi, Yan
    Qin, Rui
    Wang, Zhi-Kuan
    Dai, Guang-Hai
    ONCOTARGETS AND THERAPY, 2013, 6 : 585 - 591
  • [50] Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.
    Khasraw, Mustafa
    Mukaro, Violet Rudo
    West, Linda
    White, Karen
    Rippy, Elisabeth
    Brandt, Conrad
    Tobler, Robert
    Murphy, Caitlin Clare
    Collins, Ian M.
    Baron-Hay, Sally E.
    Ashley, David M.
    Patil, Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)